Pelloso Michela, Basso Daniela, Padoan Andrea, Fogar Paola, Plebani Mario
Department of Laboratory Medicine, University-Hospital of Padova, Padova, Italy.
Department of Medicine-DIMED, University of Padova, Padova, Italy.
J Clin Pathol. 2016 Sep;69(9):777-83. doi: 10.1136/jclinpath-2015-203447. Epub 2016 Feb 2.
To identify the best management strategy for improving the appropriateness of vitamin D, vitamin B12 and folate retesting.
The study was conducted between 3 November 2012 and 8 June 2015, with inpatients and outpatients being considered separately. After an observational reference period (3 November 2012 to 14 September 2013), an information technology (IT)-based permissive strategy (16 September 2013 to 27 July 2014) followed by a limiting strategy was used to manage the demand for inpatient retesting. For outpatients, an educational strategy period (28 July 2014 to 16 December 2014) with direct contact between medical personnel and general practitioners (GPs) was followed by a post-educational period without any restriction. Data from a total of 66 496 patients for vitamin D, 14 618 for vitamin B12 and 14 445 for folate were retrieved from the laboratory IT system. The main outcomes measures were inappropriate vitamin D, vitamin B12 and folate retesting. The minimal retesting intervals were 90 (vitamin D) or 180 days (vitamin B12 and folate).
In the absence of a laboratory demand strategy, the frequency of inappropriate retesting for vitamin D, vitamin B12 and folate was 60%, 94% and 93%, respectively, for inpatients, and 27%, 87% and 87%, respectively, for outpatients. A limiting IT-based demand management strategy reduced inappropriate retesting for vitamin D (36%), but not for vitamin B12 and folate. The educational strategy was followed by a reduction in inappropriate retesting among outpatients (16% for vitamin D, 72% for vitamin B12 and folate).
Laboratory demand management based on an IT-limiting management strategy or on education of the referring physicians appears helpful in maximising appropriate retesting.
确定改善维生素D、维生素B12和叶酸重新检测适宜性的最佳管理策略。
研究于2012年11月3日至2015年6月8日进行,住院患者和门诊患者分别进行考量。在一个观察参考期(2012年11月3日至2013年9月14日)之后,采用基于信息技术(IT)的宽松策略(2013年9月16日至2014年7月27日),随后采用限制策略来管理住院患者重新检测的需求。对于门诊患者,先是一个有医务人员与全科医生(GP)直接接触的教育策略期(2014年7月28日至2014年12月16日),之后是一个无任何限制的教育后期。从实验室IT系统中检索了总共66496例维生素D患者、14618例维生素B12患者和14445例叶酸患者的数据。主要结局指标为不适当的维生素D、维生素B12和叶酸重新检测。最小重新检测间隔为90天(维生素D)或180天(维生素B12和叶酸)。
在没有实验室需求策略的情况下,住院患者维生素D、维生素B12和叶酸不适当重新检测的频率分别为60%、94%和93%,门诊患者分别为27%、87%和87%。基于IT的限制需求管理策略减少了维生素D的不适当重新检测(36%),但对维生素B12和叶酸无效。教育策略实施后,门诊患者的不适当重新检测有所减少(维生素D为16%,维生素B12和叶酸为72%)。
基于IT限制管理策略或对转诊医生进行教育的实验室需求管理,似乎有助于使重新检测达到最佳适宜性。